ESR1 and breast cancer: The same as in this report, PURα and E2F1 were co-localized in the nuclear fraction of breast cancer cells, and AGPG disrupted the formation of the PURα/E2F1 complex to activate E2F signaling, facilitating ER-positive breast cancer cell proliferation and endocrine resistance [52].